Press Releases
2008 | 2007 | 2006 | 2005
Zelos Therapeutics to Present at Lazard Capital Markets Fourth Annual Healthcare Conference
West Conshohocken, PA, November 26, 2007 –Zelos Therapeutics today announced that Jay Mohr, Chief Business Officer of Zelos, will discuss the Company’s novel parathyroid hormone-based (PTH) therapeutics programs and provide a general corporate overview at the Lazard Capital Markets Fourth Annual Healthcare Conference taking place November 27-28, 2007 at The New York Palace Hotel in New York City. The presentation will begin at 10:00 a.m. ET on Tuesday, November 27, 2007.
About Zelos Therapeutics, Inc.
Zelos Therapeutics, Inc. is a privately held biopharmaceutical company developing novel therapies for patients suffering from conditions responsive to PTH-based therapeutics. The Company is in late-stage clinical development with Ostabolin-C™, a PTH analogue designed to improve upon the safety and efficacy of current therapies in the large and rapidly growing osteoporosis market and which may become a leading osteoporosis therapeutic. To address the need for more convenient and patient friendly, non-injectable dosing of Ostabolin-C, the Company is exploring alternative delivery methods including a collaboration with Nektar Therapeutics in the development of an inhaled dry powder formulation of Ostabolin-C. Zelos is also developing its PTH analogues in other indications, including the treatment of fracture in patients with osteoporosis.
Zelos is led by a team of seasoned biopharmaceutical executives, and is based in West Conshohocken, Pennsylvania. More information is available at www.zelostherapeutics.com.
Ostabolin-C is a trademark of Zelos Therapeutics, Inc.
